Phase II evaluation of ftorafur in previously untreated colorectal cancer: a Southwest Oncology Group Study.

Eighty-four previously untreated patients with metastatic adenocarcinoma of the large intestine received intravenous ftorafur at a dosage of 2.25 g/m2/day for 5 consecutive days. Courses were repeated every three weeks. Regressions were noted in 9 of 84 treated patients (11%). Median survival for all patients was 32 weeks. Responders survived only 5 weeks longer than nonresponders; 36 vs. 31 weeks. Central nervous system toxicity was a limiting factor occurring in one-third of patients. Ftorafur in a daily X5 schedule appears not to make a significant contribution to the management of disseminated colorectal cancer.
AuthorsT Buroker, F Padilla, C Groppe, G Guy, J Quagliana, J McCracken, V K Vaitkevicius, B Hoogstraten, L Heilbrun
JournalCancer (Cancer) Vol. 44 Issue 1 Pg. 48-51 (Jul 1979) ISSN: 0008-543X [Print] UNITED STATES
PMID378365 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Tegafur
  • Fluorouracil
  • Adenocarcinoma (drug therapy)
  • Adult
  • Aged
  • Central Nervous System (drug effects)
  • Colonic Neoplasms (drug therapy)
  • Drug Evaluation
  • Female
  • Fluorouracil (analogs & derivatives)
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Rectal Neoplasms (drug therapy)
  • Remission, Spontaneous
  • Tegafur (adverse effects, pharmacology)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: